HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer
Wook Nam, Han Kyu Chae, Yeonuk Jung, Homin Kang, Myungchan Park, Ahnryul Choi, Jong Yeon Park, Dae-Woon Eom, Sung Jin Kim · 2023
Read HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer by Wook Nam, Han Kyu Chae, Yeonuk Jung, Homin Kang, Myungchan Park, Ahnryul Choi, Jong Yeon Park, Dae-Woon Eom, Sung Jin Kim (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748406.txt.
Description
Wook Nam and co-authors look for signs that predict when BCG therapy will fail in early bladder cancer. BCG, a vaccine strain put into the bladder, is a standard treatment, but failure can force major surgery. One suspect is the HER2 protein, tied to a genetic class of these tumors.
The team reviewed 160 patients treated at one Korean hospital, 67 of whom got BCG. Tumors positive for HER2 came with worse signs, and their owners answered BCG less well. Immune cells in those tumors looked worn out. Sorting patients by HER2 and by a standard risk score, the authors argue, can flag who needs a different plan early.
Catalog record
| CREATOR | Wook Nam, Han Kyu Chae, Yeonuk Jung, Homin Kang, Myungchan Park, Ahnryul Choi, Jong Yeon Park, Dae-Woon Eom, Sung Jin Kim |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |